Pharmacogenetics of Naltrexone for Stimulant Abuse
Status:
Completed
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
This investigation will be the first study assessing genetic modulation of naltrexone's NTX
effects upon the abuse liability of a stimulant drug (methamphetamine). The study team will
assess the ability of oral NTX to block the reinforcing and positive subjective effects of
intranasal (IN) methamphetamine (30mg/70kg). This investigation could identify an important
Gene x Pharmacological interaction, contributing to the personalization of stimulant abuse
pharmacotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Treatments:
Central Nervous System Stimulants Methamphetamine Naltrexone